Accendra Health (6OM) Q2 2026 Earnings Report

The call highlighted meaningful strategic and financial progress — notably >$125M of annualized cost reductions, a successful balance sheet optimization (debt down ~ $400M and extended maturities), improving growth in sleep and diabetes, and commercial wins and operational initiatives positioned to drive late‑2026/2027 upside. However, near‑term performance was impaired by several material operational headwinds: unusually large payor audit activity that depressed collections (≈$10M in Q2, $20M H1), worsening AR and cash pressure, category weakness in respiratory and wound, and later-than-expected timing of cost benefits. Management has clear remediation plans (cost actions, collections fixes, logistics partnerships, asset sales, ATM program) and expects a stronger Q4 and improved 2027, but the near-term mix of execution and cash challenges tempers the positive long‑term narrative.

Accendra revised 2026 guidance to revenue of $2.45–$2.55 billion and full‑year adjusted EBITDA of $300–$320 million, with fully‑levered free cash flow now expected to be breakeven to slightly positive; Q2 adjusted EBITDA was just over $60 million (adjusted EBITDA less PSE CapEx $16.3 million) and Q2 revenue excluding the large payor grew ~2% (sleep ~+5.5%, diabetes +4%, insulin pumps strong, CGM weak, respiratory and wound down, ostomy/urology high single‑digit). Management said collection‑waterfall issues reduced results by roughly $10 million in Q2 and ~$20 million in H1, has eliminated >$125 million of annualized costs, completed a balance‑sheet optimization that left total debt at $1.72 billion (down ~$400 million since March) with net debt >$55 million lower, a ~5.5‑year weighted average life and no maturities until 2029, and Q2 cash interest included a $12 million cash settlement; they expect collections and cash flow to recover late 2026 into 2027, believe the business can generate roughly $100 million of annual free cash flow in a normalized year, and plan an ATM program plus an NOL rights plan to protect >$200 million of NOL carryforwards.